| 1. |
- Brezicka, Thomas, 1961
(författare)
-
Expression of epithelial-cell adhesion molecule (Ep-CAM) in small cell lung cancer as defined by monoclonal antibodies 17-1A and BerEP4
- 2005
-
Ingår i: Acta Oncol. ; 44:7, s. 723-7
-
Tidskriftsartikel (refereegranskat)abstract
- Small cell lung cancer (SCLC) comprises 15-20% of all lung cancer. Despite high initial response to chemotherapy chemoresistance at relapse leads to a less than 5% five-year survival rate. Adjuvant treatment with monoclonal antibodies (Mabs) against SCLC antigens may offer a therapeutic option. Mab 17-1A directed against the epithelial-cell adhesion molecule (Ep-CAM) has been extensively tested for therapy in patients with colorectal carcinoma. Expression of Ep-CAM in SCLC has been earlier described. However, reactivity of Mab 17-1A and another Ep-CAM-binding Mab BerEP4 has not yet been described for SCLC. Using immunohistology first with BerEP4 and confirmatory with 17-1A a homogenous and strong expression of Ep-CAM was seen in all SCLC specimens tested (n = 10). For comparison, heterogenous expression was seen in the non-SCLC tumors tested (n = 15). These findings strongly suggest that Mab 17-1A can be useful for adjuvant immunotherapy in patients with SCLC. For detection of Ep-CAM in tumor tissue in patients that might be considered for immunotherapy with Mab 17-1A, Mab BerEP4 appears to be preferred.
|
|
| 2. |
- Enarsson, Karin, 1975, et al.
(författare)
-
CD4+ CD25high regulatory T cells reduce T cell transendothelial migration in cancer patients.
- 2007
-
Ingår i: European journal of immunology. - : Wiley. - 0014-2980 .- 1521-4141. ; 37:1, s. 282-91
-
Tidskriftsartikel (refereegranskat)abstract
- Cell-mediated immunity is thought to be the main mechanism of anti-tumour responses of the host, but it is not known if cancer disease affects T cell recruitment from blood to tissues. Therefore, we compared Heliobacter pylori-induced T cell transendothelial migration (TEM) in H. pylori-infected gastric carcinoma patients, colon and lung carcinoma patients and healthy volunteers. H. pylori induced significant T cell migration from all groups. However, there was a dramatic reduction of T cell TEM in gastric carcinoma patients (80%) compared to healthy individuals. A similarly reduced transmigration was also seen in colon and lung carcinoma patients. We found significantly increased frequencies of T(reg) cells in the blood of gastric carcinoma patients compared to healthy individuals, and depletion of T(reg) cells from the blood of these patients prior to TEM restored T cell migration. The effect of T(reg) cells was largely dependent on cell-cell contact, but not on IL-10 or TGF-beta. In addition, the presence of T(reg) cells led to reduced T cell attachment to endothelium and decreased production of T cell-recruiting chemokines during TEM. In conclusion, T(reg) cell-mediated reduction of T cell TEM may reduce T cell recruitment in patients with epithelial malignancies, thereby hampering anti-tumour responses.
|
|
| 3. |
|
|
| 4. |
- Livingston, P. O., et al.
(författare)
-
Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy
- 2005
-
Ingår i: Cancer Immunol Immunother. ; 54:10
-
Tidskriftsartikel (refereegranskat)abstract
- Glycolipids GM2, GD2, GD3, fucosyl GM1, sialyl Lewis a (sLe(a)) and globo H, and polysialic acid on embryonal NCAM, are cell-surface antigens expressed on small cell lung cancer (SCLC) biopsy specimens. They are all candidates for inclusion in a polyvalent, antibody-inducing vaccine or for adoptive therapy with monoclonal antibodies (mAbs) against SCLC. To identify the minimum optimal combination of target antigens on SCLC and to confirm that antibodies against this combination might be able to mediate complement activation and lysis in the majority of cases, we tested ten SCLC cell lines with fluorescence activated cell sorter (FACS) and complement dependent cytotoxicity (CDC) assays using mAbs against these seven target antigens individually or pooled in different combinations. We find that (1) none of these mAbs demonstrated strong FACS reactivity with more than 6 of the 10 cell lines, (2) no mAb had strong CDC reactivity with more than 4 of the cell lines, (3) when the mAbs were pooled, nine cell lines were strongly positive by FACS and nine cell lines were strongly positive by CDC, and (4) mAbs against GM2, FucGM1, globo H and polysialic acid was the minimum optimal combination for inducing FACS reactivity. The addition of mAbs against sLe(a), GD2 and GD3 had no additional impact by FACS and only minimal additional impact in CDC assays. H345, the only cell line that had less than 30% CDC with the four mAb pool was strongly positive by FACS. To understand the lack of correlation between FACS and CDC in the case of H345, the ten cell lines were screened for expression of complement resistance factors CD55 and CD59. Three cell lines were strongly positive for CD55 and eight were strongly positive for CD59. Overall, no correlation was seen between expression of either of these factors on the ten cell lines and sensitivity to CDC. In the case of H345 however, complement resistance of H345 is demonstrated to be mediated primarily by CD59, and in the presence of mAb against CD59, the four mAb MEM-43 pool induced strong (94%) CDC. CD59 inhibits membrane attack complex formation but not activation of earlier complement components. Consequently, all ten cell lines are good targets for complement activation by the four antibody pool and for elimination by effector mechanisms including complement mediated inflammation and opsonization. These findings support our plan to develop a tetravalent vaccine against SCLC targeting GM2, fucosyl GM1, globo H and polysialic acid.
|
|
